Dipeptidyl peptidase-4 inhibitors: Difference between revisions
Jump to navigation
Jump to search
m Protected "Dipeptidyl peptidase-4 inhibitors": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
||
| Line 1: | Line 1: | ||
{{SI}} | {{SI}} | ||
[[Image:Incretins_and_DPP_4_inhibitors.svg|thumb|300px|left|GLP-1 and DPP-4 inhibitors]] | [[Image:Incretins_and_DPP_4_inhibitors.svg|thumb|300px|left|GLP-1 and DPP-4 inhibitors]] | ||
| Line 19: | Line 19: | ||
==External links== | ==External links== | ||
*[http://www.forbes.com/2004/01/26/cx_mh_rl_diabetestearsheet_5.html The race to get DPP-4 inhibitors to market] - Forbes.com | *[http://www.forbes.com/2004/01/26/cx_mh_rl_diabetestearsheet_5.html The race to get DPP-4 inhibitors to market] - Forbes.com | ||
{{Oral_hypoglycemics}} | {{Oral_hypoglycemics}} | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
Revision as of 00:47, 9 August 2012
Inhibitors of Dipeptidyl peptidase 4 , also DPP-4 inhibitors, are a new class of oral hypoglycemics which block DPP-4.
Their mechanism of action is thought to result from increased Incretin levels (GLP-1 and GIP),[1][2][3] which, inhibit glucagon release (which increases the blood glucose) but more importantly increase insulin secretion and decrease gastric emptying.
Drugs belonging to this class are vildagliptin[4], sitagliptin[5] and saxagliptin.
Although extensive long-term, pre-clinical studies of the major DPP-4 inhibitors has failed to show any evidence of potential to cause tumors in laboratory animals, there was one in-vitro (i.e., test tube) study that has raised some questions. [6]
References
- ↑ McIntosh CH, Demuth HU, Pospisilik JA, Pederson R. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? Regul Pept. 2005 Jun 15;128(2):159-65. PMID:15780435 [1].
- ↑ Behme MT, Dupre J, McDonald TJ. Glucagon-like peptide 1 improved glycemic control in type 1 diabetes. BMC Endocr Disord. 2003 Apr 10;3(1):3. PMID 12697069. Full Free Text.
- ↑ Dupre J, Behme MT, Hramiak IM, McFarlane P, Williamson MP, Zabel P, McDonald TJ. Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes. 1995 Jun;44(6):626-30. PMID 7789625.
- ↑ Banting and Best Diabetes Centre at UT laf237 - Vildagliptin
- ↑ Banting and Best Diabetes Centre at UT mk-0431 - Sitagliptin
- ↑ Masur K et al. DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cells, Regul Pept. ,137 (3) p. 147-55 (2006) PMID 16908079.
External links
- The race to get DPP-4 inhibitors to market - Forbes.com